Interlaboratory and intermethod variation in commercial and in-house tests used for the measurement of anticardiolipin antibodies (aCL) and lupus anticoagulant (LA) limit the diagnostic value of the results from these tests. This short review summarizes published and unpublished guidelines (some developed using consensus procedures) on aCL and LA testing that are aimed at decreasing assay variation.
A major limitation of the clinical utility of results for anticardiolipin antibody (aCL) [1] [2] [3] [4] [5] [6] [7] [8] [9] and lupus anticoagulant (LA) 1, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] tests is the often considerable variation in results obtained using different assays and laboratories. Inconsistencies have been demonstrated between different assays for both aCL 1, [3] [4] [5] 21 and LA, 1, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] as well as between laboratories using the same aCL assay. 1, 3, 5 Inconsistency in these results is important in patient care because the clinical diagnosis of the antiphospholipid syndrome (APS) depends on the demonstration of at least one of these antibodies, 22, 23 and their detection consequently influences management of conditions such as stroke and venous thrombosis that may also develop in the absence of the antibodies. Interrun and interlaboratory variation limits the portability of aCL and LA test results and, therefore, the consistency of diagnosis of the APS when patients are retested.
A fundamental predicament for the development of consensus guidelines for testing for aCL and LA is the circular nature of the definition of the APS. The 1999 Sapporo Consensus Classification Criteria require the presence of aCL or LAC in addition to a defined clinical manifestation. 23, 24 However, this is problematic because the clinical features of APS can be found in other systemic autoimmune and prothrombotic diseases. Furthermore, the use of prior serological (aCL, LA, and/or anti-b 2 -glycoprotein I [anti-b 2 -GPI]) test results to help decide whether a patient has APS will introduce an incorporation bias that will produce falsely elevated assay sensitivity and specificity values. [25] [26] [27] Thus, studies evaluating or comparing the aCL and/or LA assays cannot use the Sapporo Classification Criteria to classify patients because the criteria include the same assays that the studies are trying to evaluate. In addition, the common practice of obtaining aCL patients and controls from different populations (e.g., aCL patients from hospital clinics and controls from blood bank donors) also introduces selection and spectrum biases that may limit the generalizability of the findings. 27 To minimize these potential biases, subjects should ideally be recruited from patients presenting for the evaluation of possible APS, who are then categorized by an independent reference standard (which should not include aCL and/or LA test results) into APS patients and controls. 25 However, as discussed above, such an independent reference standard does not currently exist. Therefore, all currently published studies that evaluate aCL and LA assays are affected by these biases to some extent. This must be taken into consideration when interpreting the primary studies upon which current guidelines may be based.
Currently available tests for aCL suffer from the universal problems applicable to solid-phase assays, including source and purity of antigens, specificity of detection antibodies, and the isotype and heterogeneous spectrum of avidity of antibodies detected. The aCL assay is further complicated by the fact that it measures antibodies not only to cardiolipin but also to the cofactor b 2 -GPI. 28 Therefore, differences in the concentration of b 2 -GPI in patient sera and the reagents (diluent and blocking buffers) used also potentially influence performance of different assays. 8 The detection of LA is further compounded by issues inherent to functional assays. Many of these matters are considered in the available consensus guidelines (see below), which deal with the precision of aCL and LA testing. However, in considering this topic, we must be aware that a major problem in standardizing aCL and LA testing is improving test accuracy, which requires the identification of universally accepted, valid, and robust standards for the assays, as well as independent reference criteria (that do not incorporate aCL and/or LA results) for confirming the diagnosis of APS.
ACL TESTING Attempts at such standardization for aCL have been made at a series of international workshops. 2, [29] [30] [31] [32] The first workshop defined GPL and MPL units as 1 mg of affinity-purified immunoglobulin G (IgG) and IgM antibody that was distributed to participating laboratories. 29 Secondary standards, calibrated against initial sera, have subsequently been derived by individual laboratories and companies. However, these sera do not behave homogeneously when assayed under varying conditions because they are composed of a heterogeneous mix of polyclonal IgG and IgM antibodies. These antibodies have differing ranges of binding avidity that vary from batch to batch, and consequently behave differently when used to construct standard curves in assay design, leading to further variation in derived GPL and MPL units. Semiquantitative reporting (i.e., negative, low, medium/moderate, and high positive ranges) 2, 29 of aCL results only partially overcomes these differences in numerical results, given that discrepancies in semiquantitative results between different assays are still evident. 1, 3, 5, 8 Because of these issues with the current polyclonal standards, there is intense interest in whether the use of humanized murine monoclonal IgG and IgM antibodies with b 2 -GPI-dependent aCL activity will improve intermethod standardization. 33, 34 The European Antiphospholipid Forum 5 used monoclonal antibodies with b 2 -GPI-dependent ACL activity to construct a calibration curve in an effort to improve intermethod standardization. They demonstrated a reduction in the standard error derived for repeat testing of an IgG high positive specimen and an IgM aCL, but the reduction was not statistically significant. Additional evaluation of these monoclonal antibodies in other aCL assays with a larger range of specimens is thus required to determine whether they should replace the current polyclonal reference standards. 2 A literature search for published guidelines on aCL testing was performed using the MEDLINE database (from 1996 to 2003), the reference lists of the identified papers, and recent review articles. Three publications from the following groups were identified: the Haematology and Thrombosis Task Force of the British Committee for Standards in Haematology, 35 the European Antiphospholipid Forum, 5 and a summary of the recommendations developed during the 2001 College of American Pathologists Consensus Conference XXXVI. 36 In addition, the unpublished draft document from the National Committee for Clinical Laboratory Standards (NCCLS) entitled Detection of Anti-Cardiolipin Antibodies by ELISA; Proposed Guideline (NCCLS document I/LA22-P, Vol. 20, No. 10, ISBN 1-56238-402-3) that was released into the public domain in 2000 for comment, was obtained courtesy of Dr. W.L. Binder (Inova Diagnostics, San Diego, CA).
The main recommendations and findings from these documents are summarized in Table 1 along with recommendations from the Australasian aCL Working Comments that run should be rejected if (1) Party, published in 2004. 37 The draft NCCLS document contains the most detailed recommendations regarding technical aspects of assay manufacture, but has not been amended or published following the end of the public comment period. The publication from the European Antiphospholipid Forum 5 described 14 aspects of the consensus protocol adopted by the 19 centers involved in the study, in an attempt to reduce interlaboratory variation. The most recently published Australasian aCL Working Party consensus guidelines 37 primarily address methodology, intermethod variation, and reporting strategies. In comparison, the British Society for Standards in Haematology 35 and 2001 College of American Pathologists Consensus Conference XXXVI 36 documents contain limited details on assay manufacture and methodology.
LA TESTING Standardization of LA testing has progressed considerably over time. The International Society for Thrombosis and Haemostasis (ISTH), through its Scientific and Standardization Committee (SSC), has been attempting to deal with this issue for more than two decades. A working party on acquired inhibitors of coagulation 10 suggested criteria that were then developed by subsequent meetings of the Lupus Anticoagulant Subcommittee of the SSC into the original 1991 Guidelines for Testing and Revised Criteria for Lupus Anticoagulants. 11 These diagnostic criteria were further updated in 1995, 14 and continue to be a focus of the ISTH. 38 Other guidelines have also been published recently. 35 Published recommendations have been driven in part by some of the early ISTH laboratory surveys. 10, 12, 13 Several other laboratory-based surveys have also been reported. [15] [16] [17] 39 Like aCL, the heterogeneous nature of LA gives rise to diagnostic problems. 18 No single LA assay is 100% sensitive or specific, and a large variety of screening and confirmatory assays have been developed during the last 20 years. These assays have included various forms or modifications to procedures, including the activated partial thromboplastin time, kaolin clotting time and Russell viper venom time. These assays depend on the observation of prolongation of these clotting times. However, inhibitors other than LA and clotting factor deficiencies can also lead to prolongation of these clotting times. Therefore, confirmation of a LA using some form of phospholipid-correction test is also required. Unfortunately, there are variations in the sensitivity and specificity of different assays for LA or LA-like inhibitors. There are also reported issues with heterogeneity in reagents within test procedures, problems with calculation and reporting of results, and variation between different instruments. 16, 19 In a French survey report, less than half of a very large number of laboratories (1862 of 4500; 41%) reported detection of LA in a LA-positive plasma. 17 Misdiagnosis of LA positivity occurs when testing plasma contains factor VIII antibodies (20% of laboratories in a European Concerted Action on Thrombophilia survey 18 and 6% of laboratories in a Royal College of Pathologists of Australasia Quality Assurance Program survey 39 ) or factor deficiencies. 16, 39 Misdiagnosis of LA negativity usually occurs when weak LA-positive plasmas are tested because of the poor relative sensitivity of some assays or methods. 16, 39 The use of plasma spiked with LA-like monoclonal antibodies (i.e., monoclonal antibodies to b 2 -GPI and prothrombin) has also been assessed in two surveys. 20, 39 Although most laboratories correctly identified LA positivity in these artificially spiked plasma specimens, a significant proportion of methods or laboratories were still unable to identify this material as LA-positive. Nevertheless, as in aCL testing, such monoclonal antibodies have the potential to improve assay standardization.
Despite the occasional misdiagnosis of LA results, a comparison of various survey results during the last decade suggests that the outlook is optimistic. Error rates are generally low (< 5%) but are still reported. 15, 39 This improvement appears, in part, to be due to adoption of appropriate recommendations and lessons learned from prior errors in reported survey results. 15, 39, 40 This should provide encouragement for the ISTH and other interested bodies to continue to update and develop appropriate guidelines and criteria for the diagnosis of LA, to provide information on the standardization of methodologies, and to develop LA standards or reference plasma specimens.
CONCLUSIONS
There are several published guidelines dealing with both aCL and LA testing, many of which have been developed using consensus procedures. However, the only comprehensive guidelines (NCCLS) that deal with both technical aspects of aCL assay manufacture and interpretation/reporting issues remain in a draft and unpublished format. The relative success of current guidelines on LA testing suggests the need for similar comprehensive guidelines dealing with aCL testing.
